Bio Sketch

Dr. Gautam Panda has more than 23 years of biomedical research experience in harnessing chiral amino acids and trisubstituted methanes derived bioactive natural products, heterocycles towards drug discovery and human wellbeing. His work on cost effective synthesis of block-buster drugs is worth highlighting. He is an author of ~134 publications (3938 citations, h-index 34) and an inventor of 12 patents. 

Salient Features:

1.  Few recent leads from group: S-023-0996 exhibited 60% tumor growth inhibition at 100 mg/kg with dual inhibition of EZH2 and EGFR (0082NF2024/IN; CDRI; 09-May-2024; IN 202411036881). Administration of S-023-1025 at 100 mg/kg achieved 66% tumor growth inhibition with dual PARP and mTOR activity (0083NF2024/IN; CDRI; 15-May-2024, IN 202411038350). Another hit compound demonstrated improved hematological safety profile, distinguishing them from Olaparib (0229NF2023; IN 202411019816)  

First Biomedical Application of Bucky-Bowl corannulene derived amino acids and peptides (J. Med. Chem. 2024, 67, 17, 15041–15060. https://doi.org/10.1021/acs.jmedchem.4c00666 )

2. Filed patents on process routes ((0210NF2020); Application number IN 202111015502; (0209NF2020); Application number IN 202111003021) for two off-patented drugs (having no suppliers in India) like Almitrine and Ifenprodil which are at Phase III trials as repurposed drugs for Covid-19. Work has been shared with Reliance Rasayan Private Limited (RRPL), Ahmedabad, Gujrat. Drugs Controller General of India (DCGI) has asked to submit protocol for Phase II trial for Covid-19 patients 

3.  Discovered new process routes (0240NF2024; IN202513002027; 0009NF2022/IN; IN 202211006560; 0048NF2022/IN; IN 202211013919) of Nintedanib for non-small cell lung cancer and Olaparib to treat advanced ovarian cancer in patients with specific mutations and prior history of chemotherapy. Talks are undergoing to transfer the technology to suitable companies (Open for Licensing) 

4. Conceptualized new kind of steroidomimetics utilizing chiral amino acids. Tyrosine-derived benzoxazine lead regressed tumor growth without causing any mortality in rat syngenic mammary tumor model (J. Med. Chem. 2021, 64, 16293−16316 10.1021/acs.jmedchem.1c01624)   

5. Conceptualized trisubstituted methane S006-830 as antitubercular agents with CFU count of 2.2 x 107 with comparable efficacies to ethambutol and PZA (European Journal of Medicinal Chemistry, 95, 2015, 357-368 http://dx.doi.org/10.1016/j.ejmech.2015.03.036)

6.  Synthesized 20 bioactive natural products and their stereoisomers like inhibitors of protein kinase C (-)-Balanol and antifungal antibiotic Ophiocordin, nicotinic agonists (+)-epiquinamide and (+)-α- conhydrine, antimitotic C3-epi-(+)-lycoricidine, Jaspine B, potent inhibitor of glucosidase enzymes 8,8a-diepicastanospermine and (-)-Swainsonine, antibacterial levofloxacin and piperazinomycin, antimalarial (─)-Raphidecursinol B, novel antitumoral of marine origin spisulosine and Plinabulin, Psammaplin like, Taiwaniaquinoids etc.

7.  Critically evaluated Amino acids and Non-amino acids based synthetic approach towards bioactive natural products  

8.  Published new routes for anti-histamines Meclizine, Hydroxyzine and Cetirizine (Synthesis 2019, 51, 4434-4442) and anti-tubercular drug Bedaquiline like molecules (Journal of Molecular Structure Volume 1239, 5 September 2021, 130493) 

9. Discovered spisulosine analog that markedly induces autophagic cell death to cancer cells (European Journal of Medicinal Chemistry, 2020, 188, 112011 doi: 10.1016/j.ejmech.2019.112011. Epub 2020 Jan 2)

10. Metal free synthesis of dearylated drugs like Lasofoxifene and centchroman (Eur J Org Chem, 2019, Issue 4, 753-758 https://doi.org/10.1002/ejoc.201801375)

11. Work on chiral serine azide through Weinreb amide to reduce acidity of α-proton is widely utilized (Synlett, 2004, 4, 714-716 DOI- 10.1055/s-2004-817770 ).